Filing Details

Accession Number:
0000947871-14-000535
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-18 21:07:02
Reporting Period:
2014-08-14
Filing Date:
2014-08-18
Accepted Time:
2014-08-18 21:07:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1270073 Intercept Pharmaceuticals Inc ICPT Pharmaceutical Preparations (2834) 223868459
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055949 D Samuel Isaly 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No No No
1055951 Orbimed Advisors Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No No No
1502240 Orbimed Capital Gp Iv Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 3,704 $292.70 1,652,878 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 4,468 $293.85 1,648,410 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 3,254 $294.96 1,645,156 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 7,062 $296.21 1,638,094 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 6,192 $296.86 1,631,902 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 9,985 $297.76 1,621,917 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 100 $298.61 1,621,817 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 3,985 $300.21 1,617,832 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 1,710 $301.42 1,616,122 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 1,100 $302.55 1,615,022 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 1,193 $303.77 1,613,829 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 1,732 $305.14 1,612,097 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 525 $306.23 1,611,572 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 14,640 $307.06 1,596,932 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2014-08-14 350 $308.13 1,596,582 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $292.19 to $293.14 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $293.50 to $294.49 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $294.50 to $295.35 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $295.50 to $296.47 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  5. ) The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $296.50 to $297.425 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $297.50 to $298.10 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $300.00 to $300.95 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  8. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $301.00 to $301.98 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  9. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $302.01 to $303.00 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  10. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $303.155 to $304.13 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  11. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $304.66 to $305.50 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  12. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $305.71 to $306.65 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  13. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $307.00 to $307.69 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  14. The price reported in Column 4 is a weighted average price. These Shares of the Issuer's common stock were sold in multiple transactions at prices ranging from $308.00 to $308.40 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  15. These Shares are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the general partner of OPI IV and OrbiMed Advisors LLC ("Advisors") is the managing member of GP IV. Samuel D. Isaly ("Isaly") is the managing member of and owner of a controlling interest in Advisors and may be deemed to have voting and investment power over the Shares held by OPI IV.
  16. This Form 4 is being jointly filed by GP IV, Advisors, and Isaly. Advisors, GP IV, and Isaly have designated a representative, currently Jonathan T. Silverstein , to serve on the Issuer's board of directors.
  17. Each of GP IV, Advisors and Isaly disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.